Although IL-2 monotherapy showed early promise in metastatic renal cell carcinoma (RCC) and melanoma, its clinical utility was limited by toxicity and Treg activation, prompting a shift toward combination regimens (158, 159). This evidence concerns the gene IL2 and melanoma.